Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) Research & Development (2023 - 2025)

Historic Research & Development for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $34.4 million.

  • Zenas BioPharma's Research & Development rose 260.07% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.5 million, marking a year-over-year increase of 4628.71%. This contributed to the annual value of $139.1 million for FY2024, which is 13177.09% up from last year.
  • As of Q3 2025, Zenas BioPharma's Research & Development stood at $34.4 million, which was up 260.07% from $43.0 million recorded in Q2 2025.
  • Zenas BioPharma's Research & Development's 5-year high stood at $49.2 million during Q4 2024, with a 5-year trough of $9.4 million in Q3 2023.
  • Moreover, its 3-year median value for Research & Development was $33.8 million (2024), whereas its average is $31.3 million.
  • As far as peak fluctuations go, Zenas BioPharma's Research & Development surged by 25853.29% in 2024, and later soared by 260.07% in 2025.
  • Over the past 3 years, Zenas BioPharma's Research & Development (Quarter) stood at $20.4 million in 2023, then surged by 140.75% to $49.2 million in 2024, then plummeted by 30.02% to $34.4 million in 2025.
  • Its Research & Development stands at $34.4 million for Q3 2025, versus $43.0 million for Q2 2025 and $34.9 million for Q1 2025.